drugset
drugset / Trial / NCT03006237

IS-001 Injection Phase-1 Safety, Tolerance and Pharmacokinetics

NCT03006237 ↗

Phase 1 Completed 24 enrolled Intuitive Surgical
NaSingle-groupOpen-labelDiagnostic

Summary

A Phase 1 Open Label Single Center Safety, Tolerability and Pharmacokinetic Study of IS-001

Timeline

Start
2016-12
Primary completion
2017-12
Completion
2017-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject IS-001 Diagnostic / imaging agent 10 mg Intravenous
Subject IS-001 Diagnostic / imaging agent 20 mg Intravenous
Subject IS-001 Diagnostic / imaging agent 40 mg Intravenous

Indications

No indication recorded.